Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Windrose and Autel Validate Real-World Megawatt Charging Under MCS Standard in the Netherlands17.3.2026 10:03:00 EET | Press release
As electric heavy-duty vehicles continue to expand across Europe, charging infrastructure is evolving toward megawatt-level capability. Windrose and Autel Europe recently announced the successful completion of a real-world Megawatt Charging System (MCS) charging session at the Mega Charging Hub of a prime customer of Revolt in Roosendaal, marking an operational validation of charging under the MCS standard in live site conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313298350/en/ Windrose electric truck charging with Autel’s MCS-enabled megawatt charging system. The deployment features a modular megawatt configuration combining three MaxiCharger DS480 high-power charging cabinets connected in parallel to form a 1,440 kW system. The setup is paired with the MaxiCharger DT1500 MCS-enabled dispenser, capable of delivering up to 1.2 MW output through the MCS interface with a maximum current of 1,500 A, while also s
Aqara Enhances Smart Home Security Lineup with Camera Hub G350, and the Doorbell Camera G400 (Wired)17.3.2026 10:00:00 EET | Press release
Aqara, a global leader and pioneer in IoT, today announced the availability of the Camera Hub G350, the world’s first Matter-certified camera, and the Doorbell Camera G400 (Wired), expanding its next-generation smart home security lineup. Together, these new products deliver seamless interoperability, intelligent monitoring, and comprehensive home coverage for the modern smart home. Camera Hub G350: World’s First Matter-Certified Camera and Smart Home Controller The Aqara Camera Hub G350 marks an important milestone for Aqara as the world’s and the company’s first Matter-certified camera. Built to deliver future-ready interoperability, the G350 connects directly to Matter-enabled platforms* while offering live view, two-way audio, and alerts within the Matter-enabled ecosystem. Beyond serving as an indoor security camera, the device also functions as a Zigbee hub and Matter Controller in Aqara Home, enabling Aqara Zigbee devices and third-party Matter products to work together under un
Mobileum Showcases “Signal to Value” at MWC Barcelona 202617.3.2026 10:00:00 EET | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, highlighted its ”Signal to Value” vision at MWC Barcelona 2026, demonstrating how telecom operators can turn network events into insight, action, and revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317260292/en/ Mobileum team at MWC Barcelona 2026. At the event, Mobileum demonstrated how operators can leverage its Active Intelligence Platform to enhance roaming performance, strengthen fraud and risk defenses, and automate network assurance across increasingly complex global networks. “Operators generate massive volumes of network events every second, but the real value comes from turning those events into insights, action, and revenue,” said Bernardo Lucas, Chief Marketing & Strategy Officer at Mobileum. “At MWC 2026, Mobileum demonstrated how AI and automation can help operators move from raw telecom data to real business im
Yolanthe Cabau Honoured With Lifetime Achievement Award for Her Global Fight Against Child Sexual Exploitation17.3.2026 10:00:00 EET | Press release
During the United Nations Commission on the Status of Women Week, actress, entrepreneur and philanthropist, Yolanthe Cabau, was awarded the Lifetime Achievement Award from the New York City Bar Association in recognition of her work combating the sexual exploitation of children. Held in New York, the awards evening emphasised the importance of safety within the justice system, recognising that protecting vulnerable children also requires safeguarding the frontline teams working to create change. As the founder of the anti-child sex trafficking NGO Free a Girl, the Lifetime Achievement Award recognises Cabau’s eighteen years of dedication to rescuing children from sexual exploitation worldwide and supporting their path to justice, recovery, and empowerment. Free a Girl is a women-led organisation working to combat child sexual exploitation through undercover rescue missions that also support the identification and arrest of perpetrators. Cabau remains actively involved in the organisati
SIAL Paris 2026 : the Event That Sheds Light on and Accelerates the Global Food Business17.3.2026 10:00:00 EET | Press release
SIAL Pariswill return to Paris Nord Villepinte from 17 to 21 October 2026. The 2026 edition is set to be the most ambitious in the show’s history, surpassing an already record-breaking 2024 event and further cementing its status as a global benchmark for the food industry. SIAL Paris once again positions itself as a powerful business accelerator, an unparalleled showcase for major innovations and a strategic observatory of the trends shaping the future of food worldwide. With 85% of exhibition space already booked, up to 8,000 exhibitors expected, 295,000 professionals and more than 280,000 m² of exhibition space spanning 10 key sectors, SIAL Paris 2026 confirms both its exceptional international reach and the strong commitment of companies across the entire food value chain. A STRONG COMMERCIAL DYNAMIC AND A HIGHLY INTERNATIONAL SHOW Seven months ahead of opening, SIAL Paris 2026 is already posting strong commercial indicators. More than 260,000 m² of exhibition space has been sold, r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom